论文部分内容阅读
用可溶性肿瘤抗原和抗ＣＤ３ 单克隆抗体共同刺激外周单个核细胞（ＰＢＭＣ）产生ＣＤ＋８ Ｔ 细胞为主的杀瘤细胞，称为Ｔ－ ＡＫ 细胞。与ＬＡＫ细胞、ＣＤ３ － ＡＫ 细胞比较，Ｔ－ ＡＫ细胞扩增快、低依赖ＩＬ－ ２，培养１４ 天细胞数扩增２４ 倍，比ＣＤ３ － ＡＫ细胞高８ 倍，比ＬＡＫ细胞高１５ 倍，并能维持生长２１ 天。Ｔ－ ＡＫ细胞中含ＣＤ＋３ ８９％ ，ＣＤ＋４ ２１ ％ ，ＣＤ＋８ ９５％ ，ＣＤ＋１６ ２２％ ，ＣＤ＋２５ ４１％ ，ＣＤ＋５６ ４７ ％ ，ＣＤ＋３８ ９０ ％ ，它们是ＣＤ＋８ Ｔ细胞为主的异质性细胞群。体外实验结果表明，Ｔ－ ＡＫ细胞对Ｆｅｎ 的明显的杀伤作用，与ＬＡＫ、ＣＤ３ － ＡＫ细胞比较，差异有高度显著性（ Ｐ＜ ０．００１） 。裸鼠体内试验结果显示，对照组及ＬＡＫ组全部、ＣＤ３ － ＡＫ 组１ 只裸鼠长出瘤结节，而Ｔ－ ＡＫ组无一例长出瘤结节且生存期明显长
Using soluble tumor antigens and anti-CD3 monoclonal antibodies to stimulate peripheral blood mononuclear cells (PBMCs) to produce CD+8 T-cell-based killer cells called T-AK cells. Compared with LAK cells and CD3-AK cells, T-AK cells expanded rapidly and were lowly dependent on IL-2. The number of cells cultured 14 days was 24 times higher, 8 times higher than CD3-AK cells, and 15 times higher than LAK cells. And can maintain growth for 21 days. The T-AK cells contained CD+3 89%, CD+4 21%, CD+8 95%, CD+16 22%, CD+25 41%, CD+56 47%, and CD+38 90%. They were heterogeneous populations of CD+8 T cells. In vitro experiments showed that the apparent killing effect of T-AK cells on Fen was significantly higher than that of LAK and CD3-AK cells (P<0.001). The results of nude mice in vivo showed that no tumor nodules developed in the control and LAK groups and in one nude mouse in the CD3-AK group, while none of the T-AK group developed tumor nodules and the survival time was significantly longer.